Amydis Diagnostics, Inc. was recently given a $1.8 million Phase 2 SBIR grant by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to research and develop a novel ophthalmic diagnostic probe for Alzheimer’s Disease.
According to the company, build-up and deposition of amyloid-beta plaques in the brain is currently the leading biomarker for early detection of Alzheimer’s Disease. Current diagnostic procedures to detect amyloid-beta in the brain are reportedly based on brain imaging techniques or biochemical assays following an invasive procedure. Amydis reportedly aims to create a less costly, non-invasive diagnostic procedures based on ophthalmologic procedures.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: Amydis Diagnostics, Inc.